-
Innovation Ranking
NewInnovation Ranking – AIM ImmunoTech Inc
AIM ImmunoTech Inc (AIM ImmunoTech), formerly Hemispherx Biopharma Inc, is an immuno- pharma company. The company focuses on the research and development of therapeutics for the treatment of multiple types of cancers, viruses and immune-deficiency disorders. Its flagship products include Ampligen (rintatolimod) sterile solution which is indicated for the treatment of patients with chronic fatigue syndrome; and Alferon N Injection used for the treatment of refractory or recurrent external condylomata acuminate. The company’s pipeline products are intended to treat various...
-
Product Insights
NewNet Present Value Model: Aldeyra Therapeutics Inc’s Reproxalap
Empower your strategies with our Net Present Value Model: Aldeyra Therapeutics Inc's Reproxalap report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rintatolimod in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rintatolimod in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rintatolimod in Triple-Negative Breast Cancer (TNBC) Drug Details: Ampligen...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rintatolimod in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rintatolimod in Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rintatolimod in Prostate Cancer Drug Details: Ampligen is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rintatolimod in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rintatolimod in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rintatolimod in Melanoma Drug Details: Ampligen is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Rintatolimod in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rintatolimod in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rintatolimod in Metastatic Colorectal Cancer Drug Details: Ampligen is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Rintatolimod in Chronic Fatigue Syndrome (Myalgic Encephalomyelitis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rintatolimod in Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rintatolimod in Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KAND-567 in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KAND-567 in Peritoneal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KAND-567 in Peritoneal Cancer Drug Details: KAND-567 (AZD-8797) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SCT-200 in Esophageal Squamous Cell Carcinoma (ESCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SCT-200 in Esophageal Squamous Cell Carcinoma (ESCC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SCT-200 in Esophageal Squamous Cell Carcinoma (ESCC) Drug Details:...